Pralsetinib is an oral rearranged during transfection (RET) tyrosine kinase inhibitor (TKI) that inhibits oncogenic RET fusions and mutations.1 The purpose of this PQI is to review pralsetinibs role in therapy, management of adverse effects, potential drug interactions, and to recommend patient follow-up associated with pralsetinib treatment.